Verona Pharma: Publication of Phase 3 COPD Data

 Ensifentrine improved lung function, symptoms and quality of life and reduced exacerbations in data published in high impact peer reviewed journal

Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the American Journal of Respiratory and Critical Care Medicine (“AJRCCM”) has published results from its Phase 3 ENHANCE trials evaluating ensifentrine in chronic obstructive pulmonary disease (“COPD”).

The publication reports results from Verona Pharma’s successful ENHANCE trials demonstrating improvements with ensifentrine in lung function, symptoms and quality of life measures, as well as a substantial reduction in the rate and risk of COPD exacerbations and a favourable safety profile. The manuscript, entitled ‘Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials)’, is available online here and will be published in an upcoming issue of AJRCCM. It follows announcements of top-line data from the ENHANCE-1 and ENHANCE-2 trials in December and August 2022, respectively.

https://www.biospace.com/article/releases/verona-pharma-announces-publication-of-phase-3-enhance-data-in-the-american-journal-of-respiratory-and-critical-care-medicine/